Can selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) offer protection against contrast induced nephropathy?
Authors:
- Sameh K. MorcosSMSameh K. Morcos
- Sameh K.SKSameh K.
Open Access
- 1 August 2014
- journal article
- editorial
- Vol. 4 (4) , 214-215-215
Abstract
Can selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) offer protection against contrast induced nephropathy?Keywords
This publication has 13 references indexed in Scilit:
- Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelinesEuropean Radiology, 2011
- Reactive Oxygen Species and the Pathogenesis of Radiocontrast-Induced NephropathyInvestigative Radiology, 2010
- Renal Parenchymal Hypoxia, Hypoxia Adaptation, and the Pathogenesis of Radiocontrast NephropathyClinical Journal of the American Society of Nephrology, 2008
- Tadalafil pharmacokinetics in healthy subjectsBritish Journal of Clinical Pharmacology, 2005
- Prevention of contrast media nephrotoxicity—the story so farClinical Radiology, 2004
- Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 1998
- Contrast media-induced nephrotoxicity--questions and answers.British Journal of Radiology, 1998
- Sildenafil, a novel effective oral therapy for male erectile dysfunctionBritish Journal of Urology, 1996
- Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.1996
- Hypoxia of the Renal Medulla — Its Implications for DiseaseNew England Journal of Medicine, 1995